We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
51
Ventas
VTR
$44.7B
$12.2M 0.45%
175,991
– –
SGEN
52
DELISTED
Seagen Inc. Common Stock
SGEN
$11.6M 0.43%
+223,700
New +$14.2M
ACHC icon
53
Acadia Healthcare
ACHC
$2.62B
$11.4M 0.42%
231,200
– –
DERM
54
DELISTED
Dermira, Inc.
DERM
$11.3M 0.42%
386,900
+221,700
+134% +$6.74M
AKRX
55
DELISTED
Akorn Inc
AKRX
$11M 0.41%
327,735
– –
DOC
56
DELISTED
PHYSICIANS REALTY TRUST
DOC
$10.7M 0.4%
530,672
– –
BMY icon
57
Bristol-Myers Squibb
BMY
$132B
$10.4M 0.39%
186,500
– –
ENDP
58
DELISTED
Endo International plc
ENDP
$10.2M 0.38%
914,548
– –
NVO
59
Novo Nordisk
NVO
$228B
$9.32M 0.35%
434,600
+268,600
+162% +$5.42M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$27.4B
$9.17M 0.34%
114,966
-129,029
-53% -$8.25M
SNY icon
61
Sanofi
SNY
$103B
$8.62M 0.32%
179,900
-125,100
-41% -$5.98M
HCA icon
62
HCA Healthcare
HCA
$85.7B
$8.3M 0.31%
95,232
+31,800
+50% +$2.69M
CTMX icon
63
CytomX Therapeutics
CTMX
$714M
$8.22M 0.3%
530,092
– –
CLLS
64
Cellectis
CLLS
$287M
$8.01M 0.3%
310,250
– –
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.56B
$7.91M 0.29%
127,308
+38,908
+44% +$2.34M
PRAH
66
DELISTED
PRA Health Sciences, Inc.
PRAH
$7.65M 0.28%
102,000
– –
MRUS
67
DELISTED
Merus
MRUS
$7.59M 0.28%
479,150
– –
BHC icon
68
Bausch Health
BHC
$2.25B
$7.44M 0.28%
430,000
+238,000
+124% +$2.85M
RARX
69
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.42M 0.27%
+395,818
New +$8.93M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$7.21M 0.27%
90,480
– –
TTPH
71
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$7.16M 0.27%
50,216
– –
LTC
72
LTC Properties
LTC
$2.06B
$7M 0.26%
136,212
– –
AVDL
73
DELISTED
Avadel Pharmaceuticals
AVDL
$6.89M 0.26%
624,288
– –
KPTI icon
74
Karyopharm Therapeutics
KPTI
$159M
$6.85M 0.25%
50,445
+10,097
+25% +$1.49M
DPLO
75
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$6.83M 0.25%
461,712
+331,489
+255% +$5.52M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.